Subscribe
Tuesday, September 15, 2026
26.9 C
Bengaluru
type here...
Subscribe
Exclusive ReportMedical DevicesHealthcare News
9 min.Read

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

Anup Soans
By Anup Soans

The Semaglutide Shift: From Blockbuster to Commodity Why the $50 API crash is not a crisis of value—but a crisis of differentiation. And what Indian pharma must learn from mobile phones, insulin pens, and chai stalls. Imagine you are selling mobile phones in 2010. Having a smartphone at all was a huge deal. You could…

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

MedicinMan Market Intelligence

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...
MedicinMan Pharma Pulse

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...
Digital in Pharma

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

0
How wearables, diagnostics, AI and continuous monitoring are moving...
Featured Article

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

0
RPG Active Pharma’s agreement to acquire the API and...
Healthcare Ececutive

Pharmacy of the World Pricing Paradox

0
India occupies an extraordinary position in global pharmaceuticals. It...

Topics

MedicinMan Market Intelligence

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...
MedicinMan Pharma Pulse

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...
Digital in Pharma

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

0
How wearables, diagnostics, AI and continuous monitoring are moving...
Featured Article

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

0
RPG Active Pharma’s agreement to acquire the API and...
Healthcare Ececutive

Pharmacy of the World Pricing Paradox

0
India occupies an extraordinary position in global pharmaceuticals. It...
Featured Article

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

0
India has two very different pharmaceutical regulators living inside...
MedicinMan Pharma Pulse

MedicinMan Pharma Pulse: August 2026

0
🚀 The Mega-Merger That Wasn't Early August saw the...
Featured Article

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

0
STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...
spot_img

Related Articles

spot_imgspot_img
Previous article
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
Next article
Will the GLP Battle Now Shift from Injectable to Oral?

MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More

Company

Headlines

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

0
How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

0
RPG Active Pharma’s agreement to acquire the API and...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 | Crafted by SlamDunk